The company has received SEK 5 million from Eurostars in a collaborative project with the French biotech company Okomera.

The funding is intended to strengthen the development of an analysis method for T-cell activity against the patient’s tumor.

“We are very grateful for the support from Eurostars, which not only recognizes the scientific potential of our company, but also reinforces our role as an innovator in analytical methods for next-generation cell therapies. The funding enables in-depth research that is important to be able to take our cell therapy product to later clinical stages phases,” says Samuel Svensson, CEO of Neogap Therapeutics.

Within the framework of the Eurostars-funded project, Neogap collaborates with Okomera, which has developed a method for the analysis of cell interactions. The method enables analysis of how T cells kill tumor cells in a so-called killing assay with only minimal use of the cell product. This analysis will provide in-depth knowledge of the interaction between T cells and tumor cells and optimally can also be used to predict the effectiveness of Neogap’s cell therapy products, the company states. The goal is to develop a system to easily and reliably measure Neogap’s T-cell product pTTL’s ability to kill cancer cells.

Photo: Neogap